Literature DB >> 27412458

Gold silver alloy nanoparticles (GSAN): an imaging probe for breast cancer screening with dual-energy mammography or computed tomography.

Pratap C Naha1, Kristen C Lau1, Jessica C Hsu2, Maryam Hajfathalian3, Shaameen Mian4, Peter Chhour2, Lahari Uppuluri1, Elizabeth S McDonald1, Andrew D A Maidment1, David P Cormode5.   

Abstract

Earlier detection of breast cancer reduces mortality from this disease. As a result, the development of better screening techniques is a topic of intense interest. Contrast-enhanced dual-energy mammography (DEM) is a novel technique that has improved sensitivity for cancer detection. However, the development of contrast agents for this technique is in its infancy. We herein report gold-silver alloy nanoparticles (GSAN) that have potent DEM contrast properties and improved biocompatibility. GSAN formulations containing a range of gold : silver ratios and capped with m-PEG were synthesized and characterized using various analytical methods. DEM and computed tomography (CT) phantom imaging showed that GSAN produced robust contrast that was comparable to silver alone. Cell viability, reactive oxygen species generation and DNA damage results revealed that the formulations with 30% or higher gold content are cytocompatible to Hep G2 and J774A.1 cells. In vivo imaging was performed in mice with and without breast tumors. The results showed that GSAN produce strong DEM and CT contrast and accumulated in tumors. Furthermore, both in vivo imaging and ex vivo analysis indicated the excretion of GSAN via both urine and feces. In summary, GSAN produce strong DEM and CT contrast, and has potential for both blood pool imaging and for breast cancer screening.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27412458      PMCID: PMC4955565          DOI: 10.1039/c6nr02618d

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  59 in total

1.  Contrast-enhanced dedicated breast CT: initial clinical experience.

Authors:  Nicolas D Prionas; Karen K Lindfors; Shonket Ray; Shih-Ying Huang; Laurel A Beckett; Wayne L Monsky; John M Boone
Journal:  Radiology       Date:  2010-09       Impact factor: 11.105

2.  Development of silica-encapsulated silver nanoparticles as contrast agents intended for dual-energy mammography.

Authors:  Roshan Karunamuni; Pratap C Naha; Kristen C Lau; Ajlan Al-Zaki; Anatoliy V Popov; Edward J Delikatny; Andrew Tsourkas; David P Cormode; Andrew D A Maidment
Journal:  Eur Radiol       Date:  2016-02-24       Impact factor: 5.315

3.  Exploring silver as a contrast agent for contrast-enhanced dual-energy X-ray breast imaging.

Authors:  R Karunamuni; A Tsourkas; A D A Maidment
Journal:  Br J Radiol       Date:  2014-07-07       Impact factor: 3.039

4.  X-ray CT and pneumonia inhibition properties of gold-silver nanoparticles for targeting MRSA induced pneumonia.

Authors:  Da Huo; Jing Ding; Yi X Cui; Lu Y Xia; Hui Li; Jian He; Zheng Y Zhou; Hong W Wang; Yong Hu
Journal:  Biomaterials       Date:  2014-05-15       Impact factor: 12.479

Review 5.  Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects.

Authors:  Richard Solomon; William Dumouchel
Journal:  Invest Radiol       Date:  2006-08       Impact factor: 6.016

Review 6.  Contrast-enhanced digital mammography.

Authors:  Maxine Jochelson
Journal:  Radiol Clin North Am       Date:  2014-01-18       Impact factor: 2.303

7.  Effect of computed tomography scanning parameters on gold nanoparticle and iodine contrast.

Authors:  Merav Weill Galper; May Tun Saung; Valentin Fuster; Ewald Roessl; Axel Thran; Roland Proksa; Zahi Adel Fayad; David Peter Cormode
Journal:  Invest Radiol       Date:  2012-08       Impact factor: 6.016

8.  Dextran coated bismuth-iron oxide nanohybrid contrast agents for computed tomography and magnetic resonance imaging.

Authors:  Pratap C Naha; Ajlan Al Zaki; Elizabeth Hecht; Michael Chorny; Peter Chhour; Eric Blankemeyer; Douglas M Yates; Walter R T Witschey; Harold I Litt; Andrew Tsourkas; David P Cormode
Journal:  J Mater Chem B       Date:  2014-12-14       Impact factor: 6.331

Review 9.  Dense breasts: a review of reporting legislation and available supplemental screening options.

Authors:  Jessica M Ho; Nasima Jafferjee; Gabriel M Covarrubias; Munir Ghesani; Bradley Handler
Journal:  AJR Am J Roentgenol       Date:  2014-08       Impact factor: 3.959

10.  Synthesis, X-ray Opacity, and Biological Compatibility of Ultra-High Payload Elemental Bismuth Nanoparticle X-ray Contrast Agents.

Authors:  Anna L Brown; Pratap C Naha; Victor Benavides-Montes; Harold I Litt; Andrea M Goforth; David P Cormode
Journal:  Chem Mater       Date:  2014-03-10       Impact factor: 9.811

View more
  28 in total

1.  An all-in-one nanoparticle (AION) contrast agent for breast cancer screening with DEM-CT-MRI-NIRF imaging.

Authors:  Jessica C Hsu; Pratap C Naha; Kristen C Lau; Peter Chhour; Renee Hastings; Brianna F Moon; Joel M Stein; Walter R T Witschey; Elizabeth S McDonald; Andrew D A Maidment; David P Cormode
Journal:  Nanoscale       Date:  2018-09-20       Impact factor: 7.790

Review 2.  Nanoparticle contrast agents for X-ray imaging applications.

Authors:  Jessica C Hsu; Lenitza M Nieves; Oshra Betzer; Tamar Sadan; Peter B Noël; Rachela Popovtzer; David P Cormode
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-05-22

3.  Water-Dispersible Bismuth-Organic Materials with Computed Tomography Contrast Properties.

Authors:  Guoxian Zhang; Pratap C Naha; Prabhat Gautam; David P Cormode; Julian M W Chan
Journal:  ACS Appl Bio Mater       Date:  2018-11-12

4.  Intra- and Extracellular Biosynthesis and Characterization of Iron Nanoparticles from Prokaryotic Microorganisms with Anticoagulant Activity.

Authors:  Karina A Crespo; José L Baronetti; Melisa A Quinteros; Paulina L Páez; María G Paraje
Journal:  Pharm Res       Date:  2016-12-19       Impact factor: 4.200

5.  Evaluation of spectral photon counting computed tomography K-edge imaging for determination of gold nanoparticle biodistribution in vivo.

Authors:  Salim Si-Mohamed; David P Cormode; Daniel Bar-Ness; Monica Sigovan; Pratap C Naha; Jean-Baptiste Langlois; Lara Chalabreysse; Philippe Coulon; Ira Blevis; Ewald Roessl; Klaus Erhard; Loic Boussel; Philippe Douek
Journal:  Nanoscale       Date:  2017-11-30       Impact factor: 7.790

6.  Dextran-Coated Iron Oxide Nanoparticles as Biomimetic Catalysts for Localized and pH-Activated Biofilm Disruption.

Authors:  Pratap C Naha; Yuan Liu; Geelsu Hwang; Yue Huang; Sarah Gubara; Venkata Jonnakuti; Aurea Simon-Soro; Dongyeop Kim; Lizeng Gao; Hyun Koo; David P Cormode
Journal:  ACS Nano       Date:  2019-01-22       Impact factor: 15.881

7.  Wulff in a cage gold nanoparticles as contrast agents for computed tomography and photoacoustic imaging.

Authors:  Maryam Hajfathalian; Ahmad Amirshaghaghi; Pratap C Naha; Peter Chhour; Jessica C Hsu; Keely Douglas; Yuxi Dong; Chandra M Sehgal; Andrew Tsourkas; Svetlana Neretina; David P Cormode
Journal:  Nanoscale       Date:  2018-10-02       Impact factor: 7.790

8.  Dextran-Coated Cerium Oxide Nanoparticles: A Computed Tomography Contrast Agent for Imaging the Gastrointestinal Tract and Inflammatory Bowel Disease.

Authors:  Pratap C Naha; Jessica C Hsu; Johoon Kim; Shrey Shah; Mathilde Bouché; Salim Si-Mohamed; Derick N Rosario-Berrios; Philippe Douek; Maryam Hajfathalian; Parisa Yasini; Sanjay Singh; Mark A Rosen; Matthew A Morgan; David P Cormode
Journal:  ACS Nano       Date:  2020-07-28       Impact factor: 15.881

Review 9.  Emerging Biomedical Applications of Enzyme-Like Catalytic Nanomaterials.

Authors:  David P Cormode; Lizeng Gao; Hyun Koo
Journal:  Trends Biotechnol       Date:  2017-10-26       Impact factor: 19.536

10.  Silver telluride nanoparticles as biocompatible and enhanced contrast agents for X-ray imaging: an in vivo breast cancer screening study.

Authors:  Lenitza M Nieves; Jessica C Hsu; Kristen C Lau; Andrew D A Maidment; David P Cormode
Journal:  Nanoscale       Date:  2021-01-08       Impact factor: 7.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.